Data updated: May 26, 2026
INZIRQO (hydrochlorothiazide)
Cardiovascular
Approved 2025-01-28
INZIRQO is a thiazide diuretic used for adults and children to manage high blood pressure and reduce the risk of serious heart-related events like strokes and heart attacks. It also helps patients with swelling, or edema, caused by heart failure, liver cirrhosis, or kidney diseases such as nephrotic syndrome. Doctors often prescribe it as part of a broader plan to manage cardiovascular health, which
1
Indication
--
Phase 3 Trials
1
Years on Market
Details
- Status
- Prescription
- First Approved
- 2025-01-28
- Patent Cliff
- 2044
- Routes
- ORAL
- Dosage Forms
- FOR SUSPENSION
INZIRQO Approval History
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2025 to 2025
What INZIRQO Treats
6 indicationsINZIRQO is approved for 6 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Hypertension
- Edema
- Congestive Heart Failure
- Hepatic Cirrhosis
- Renal Disease
- Nephrotic Syndrome
Source: FDA Label
INZIRQO Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
10
Same indication, different mechanism — what else might this patient receive?
Unlock 8 more competitors across all three rings.
Upgrade to Pro Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in INZIRQO's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications INZIRQO treats. First-in-class if their pivotal trials read out positive.
Baxdrostat CIN-107 ✓ Won — Ph3 readout
AstraZeneca CYP11B2 · small-molecule selective aldosterone synthase inhibitor · 4 Phase 3 trials
Lorundrostat MLS-101 ✓ Won — Ph3 readout
Mineralys Therapeutics Inc. CYP11B2 · small-molecule selective aldosterone synthase inhibitor · 2 Phase 3 trials
Zilebesiran ALN-AGT01
Alnylam Pharmaceuticals AGT · GalNAc-conjugated siRNA (RNAi therapeutic) · 1 Phase 3 trial
Drugs Similar to INZIRQO
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
📋
Clinical Trial Registry
45 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT03892148 ProDUCT-HF | CHU-428 2018-A02971-54 | Ph 4 | completed | Protocol of Diuretics Use in Congestive Therapy in Heart Failure |
| NCT04654312 | HCTox | Ph 1 | completed | Study to Evaluate the Influence of Hydrochlorothiazide on Dermal Photosensitivity and DNA Stability - a Pilot Study (HCTox Study) |
| NCT02373163 INTERVENCION results posted | INTERVENCION Trial | Ph 4 | completed | INTERVENCION Trial |
| NCT03109795 ATLAS results posted | 201701762 | Ph 4 | terminated | Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System |
| NCT05917275 HT-PREDICT | 114516 2023-505239-10-00 | Ph 4 | recruiting | Multi-Omics to Predict the Blood Pressure Response to Antihypertensives |
| NCT03179163 H2SPharm results posted | STUDY3224 5R01HL093238, 120058 | Ph 1, Ph 2 | terminated | Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans |
| NCT01983462 VANISH results posted | 201307779 | Ph 2 | terminated | Vascular Dysfunction in Human Obesity Hypertension |
| NCT01647932 CLOROTIC | SEMI-IC-CLOR | Ph 3 | completed | Safety and Efficacy of the Combination of Loop With Thiazide-type Diuretics in Patients With Decompensated Heart Failure |
| NCT03461003 NICHE results posted | HSC-MS-17-1014 UL1TR003167 | Ph 4 | completed | N-of-1 Trials In Children With Hypertension |
| NCT03387657 | INT14905 U1111-1186-2718 | Ph 1 | completed | A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide |
| NCT00667719 results posted | CSAH100A2301 2008-001242-10 | Ph 3 | completed | A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension |
| NCT02699125 guanhctz results posted | guanhctz | Ph 4 | completed | Treatment of OSA Associated Hypertension With Alpha 2 Agonist or Diuretic |
| NCT02710071 nebhctz results posted | 110342 | Ph 4 | completed | Treatment of OSA Associated Hypertension With Nebivolol or Hydrochlorothiazide |
| NCT03170336 ANTI-UPRO | GGH2016422H | Ph 4 | completed | A New Application of Amiloride in the Treatment of Patient With Chronic Kidney Disease In Reducing Urinary PROtein |
| NCT00765947 results posted | CSPP100A2360 | Ph 4 | completed | Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension |
| NCT01519635 results posted | 2011DR3137 | Ph 4 | completed | Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension |
| NCT04197622 HCTZ | IMIMFTCL/HCTZ | Ph 1 | completed | Generation of Biological Samples Positive to Hydrochlorothiazide for Anti-doping Control |
| NCT03889145 | ID-TAH-1301 | Ph 1 | completed | A Study to Evaluate the Drug-drug Interaction Between Telmisartan, Amlodipine and Hydrochlorothiazide |
| NCT00649389 results posted | CS8635-A-U301 | Ph 3 | completed | Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension |
| NCT02875886 DD | NL54748.078.15 | Ph 4 | completed | DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease |
| NCT00994253 | 2009-083 | Ph 4 | withdrawn | Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics |
| NCT01748123 | PCORI-EGID 4231 00041242 | Ph 4 | withdrawn | EBMtrialcentral- Comparing Initial Diuretic Therapies Using a Collaborative Network |
| NCT00976495 results posted | MB102-035 EUDRACT #: 2009-010221-39 | Ph 2 | completed | Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes |
| NCT02739672 | ID-TAH-102 | Ph 1 | completed | Clinical Trial to Compare the Pharmacokinetics of TAH Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers |
| NCT03032315 | ID-TAH-103 | Ph 1 | completed | Compare the Pharmacokinetics of TAH(80/10/12.5) Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers |
| NCT01975246 results posted | 1348.1 | Ph 3 | completed | Add-on to Micamlo BP Trial |
| NCT01365481 results posted | CVAL489K2305 2009-017594-37 | Ph 3 | completed | Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age |
| NCT02222480 | BR-FHC-CT-201-BZ | Ph 2 | completed | A Clinical Trial to Evaluate Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan/Hydrochlorothiazide |
| NCT01692301 results posted | CLCZ696A2216 2012-002899-14 | Ph 2 | completed | Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension |
| NCT01480791 | CSPP100ACA03T | Ph 2 | withdrawn | Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries |
| NCT01922141 ASSESS | CSPP100A2370 2013-001562-42 | Ph 4 | withdrawn | Aliskiren Study of Safety and Efficacy in Senior Hypertensives |
| NCT01276288 results posted | 1245.42 2010-019624-31 | Ph 1 | completed | Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes |
| NCT00926289 results posted | 502.550 2008-007711-32 | Ph 4 | completed | Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension |
| NCT01172431 | WestChinaH | Ph 4 | completed | Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency |
| NCT02072330 | TAK-536TCH/CCT-001 JapicCTI-121962 | Ph 2, Ph 3 | completed | Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension. |
| NCT00605072 AVEC results posted | IA0127 K23AG030057 | Ph 2 | completed | The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial |
| NCT01138423 TARGET | UMCU-Vasc-14A | Ph 4 | completed | Treatment of Adiposity Related hypErTension (TARGET) |
| NCT00797862 ACCELERATE results posted | CSPA100A2307 | Ph 3 | completed | Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension |
| NCT00980187 AISHA | RO-SCL-IQ v 1.0/04.07 | Ph 4 | completed | A Comparison of Indapamide SR 1.5 mg With HCTZ 25 mg, in Combination With an ACE-inhibitor, in Patients With Mild to Moderate AHT and Type 2 DM |
| NCT00760266 ACTION results posted | CSPP100A2411 | Ph 4 | completed | Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population |
| NCT00797316 AIMS results posted | CSPP100A2410 | Ph 4 | completed | Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension |
| NCT00654745 results posted | CS-8663-403 | Ph 4 | completed | 18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics |
| NCT00621153 CAESAR results posted | D2452L00016 | Ph 4 | completed | Candesartan Effect in Second Stage Arterial Hypertension |
| NCT00605202 results posted | Lakritsi ja hypokalemia | Ph 4 | completed | Effect of Licorice and Hydrochlorothiazide on Plasma Potassium |
| NCT00923533 | A657-BR-CT-103 | Ph 1 | completed | A Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Fimasartan and Hydrochlorothiazide in Healthy Male Volunteers |
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
INZIRQO FDA Label Details
Indications & Usage
FDA Label (PDF)INZIRQO is indicated for the treatment of Hypertension; Edema; Congestive Heart Failure; Hepatic Cirrhosis; Renal Disease; Nephrotic Syndrome.
View full patent landscape →
1 OB patents · 1 families ·
2 international docs across 1 countries
INZIRQO Patents & Exclusivity
Latest Patent: Jan 2044
Patents (1 active)
US11878022
Expires Jan 23, 2044
Source: FDA Orange Book
Pro Intelligence Preview
Deep insights for INZIRQO
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2044
- • 2 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Unlock Full Intelligence
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.